Immunology of Ebola Vaccine

Eligibility Criteria

• * Signed informed consent for study.
• * For women of childbearing potential: willing to engage in effective methods of contraception starting at least 28 days prior to vaccination and during the study.
• * Willing to minimize blood and body fluid exposure to others (encourage abstinence, and hand hygiene; discourage contact with blood, vomit, feces without personal protective equipment (PPE) for at least 14 days following vaccine administration.
• * Willing to forgo blood donation until 56 days following vaccination.
• * At risk of travel-related or occupational exposure to Ebola virus such as through laboratory, clinical contact, field work, or in the judgment of the investigator.
• * Received any Ebola vaccines or have history of Ebola Virus Disease (EVD).
• * Current or previous diagnosis of immunocompromising condition such as human immunodeficiency virus or other immunosuppressive condition by receiving systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 6 months prior to screening (for corticosteroids: ≥ 10mg/day of prednisone or equivalent) or anticipates the need for immunosuppressive treatment at any time during participation in the study.
• * Pregnant and/or breastfeeding (must have urine pregnancy test on the day of vaccination and during screening visit)
• * Known allergy to any component of the rVSV∆G-ZEBOV-GP vaccine products (VSV, albumin, tris).
• * History of severe local or systemic reactions to any vaccination.
• * Received investigational drug within 5 half-lives or 28 days, whichever is longer, prior to study vaccination.
• * Received or intends to receive vaccines within 28 days prior to or following study vaccination.
• * Received immunoglobulins and/or any blood products within 120 days prior to study vaccination.
• * Clinical evidence of systemic infection or other acute intercurrent illness (e.g. oral temp \>38°C or \> 100.4°F) less than 72 hours prior to study vaccination.
• * Currently has symptomatic, acute, or unstable chronic disease requiring medical or surgical care, to include significant change in therapy or hospitalization, at the discretion of the investigator.
• * History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions, or occupational conditions that in the opinion of the investigator would preclude compliance with the study.
• * Any condition that would limit the ability of the participant to meet protocol requirements or would place the participant at unreasonable risk in the opinion of the investigator.